Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 7:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–3 of 3 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Sporadic Thyroid Gland Medullary Carcinoma Clear all

Terminated Phase 1Phase 2 Interventional Results available

A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)

NCT00923247

View directory record Official record

Conditions: Medullary Thyroid Carcinoma
Interventions: Bortezomib, Vandetanib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 80 Years

Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Source: ClinicalTrials.gov public record

Updated Nov 28, 2018 · Synced May 21, 2026, 7:24 PM EDT

Completed Phase 2 Interventional Results available

Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer

NCT00390325

View directory record Official record

Conditions: Hereditary Thyroid Gland Medullary Carcinoma, Locally Advanced Thyroid Gland Medullary Carcinoma, Multiple Endocrine Neoplasia Type 2A, Multiple Endocrine Neoplasia Type 2B, Recurrent Thyroid Gland Medullary Carcinoma, Sporadic Thyroid Gland Medullary Carcinoma, Stage III Thyroid Gland Medullary Carcinoma AJCC v7, Stage IV Thyroid Gland Medullary Carcinoma AJCC v7, Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7, Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7, Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7
Interventions: Sorafenib Tosylate; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older

Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2022
U.S. locations: 3
States / cities: St Louis, Missouri • Durham, North Carolina • Columbus, Ohio

Source: ClinicalTrials.gov public record

Updated Feb 5, 2024 · Synced May 21, 2026, 7:24 PM EDT

Completed Phase 3 Interventional Results available

An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer

NCT00410761

View directory record Official record

Conditions: Thyroid Cancer
Interventions: ZD6474 (Vandetanib); Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older

Enrollment: 331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2024
U.S. locations: 32
States / cities: Little Rock, Arkansas • San Francisco, California • Aurora, Colorado + 13 more

Source: ClinicalTrials.gov public record

Updated Sep 23, 2025 · Synced May 21, 2026, 7:24 PM EDT